Jose Munoz Olaya
About Jose Munoz Olaya
Jose Munoz-Olaya is the CSO with extensive experience in antibody discovery and preclinical development, having held significant roles at Valink Therapeutics, Takeda, and F-star Therapeutics.
Jose Munoz-Olaya CSO at Valink Therapeutics
Jose Munoz-Olaya serves as the Chief Scientific Officer (CSO) at Valink Therapeutics. He brings over a decade of experience in antibody discovery and preclinical development within the biotech and pharmaceutical industries. His role at Valink Therapeutics builds on a strong foundation of expertise, having joined from Takeda. Throughout his career, Jose has demonstrated a commitment to advancing therapeutic programs from the discovery phase through clinical development.
Jose Munoz-Olaya's Experience at Takeda
At Takeda, Jose Munoz-Olaya played a crucial role in progressing various programs from the discovery phase through clinical development. His tenure at Takeda allowed him to refine his expertise in preclinical development and antibody discovery. This experience has been essential in shaping his approach to drug development at Valink Therapeutics, emphasizing the transition from early-stage discovery to clinical application.
Jose Munoz-Olaya's Role at F-star Therapeutics
During his time with F-star Therapeutics, Jose Munoz-Olaya led immune cell engager programs from their inception to pre-Investigational New Drug (pre-IND) stages and subsequently into Phase I trials. His efforts spanned various drug candidates, contributing to multiple publications and patents. In addition to leading these programs, he occupied key positions in platform, technology, and pharmacology development at F-star.
Jose Munoz-Olaya's Scientific Roles at AstraZeneca and Cambridge Antibody Technology
Before joining Adaptate, which was later acquired by Takeda, Jose Munoz-Olaya held scientific roles within AstraZeneca and Cambridge Antibody Technology. In these positions, he worked on advancing the understanding and development of therapeutic antibodies and multifunctional proteins, contributing to the growth of these companies' research and development capabilities.
Jose Munoz-Olaya's Interest in Multispecific Antibodies
Jose Munoz-Olaya has a keen interest in the development of multispecific antibodies and multifunctional proteins. He is particularly intrigued by the potential of these drugs in addressing areas with highly unmet clinical needs. His work in this field aims to harness the innovative capabilities of multispecific antibodies to improve therapeutic outcomes in challenging medical conditions.